Colon and Rectal Cancer Study
CALGB 80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Parients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
Protocol ID
06.06.001T
Protocol Description
This study is being done to find out the effects (good and bad) of different regimens of chemotherapy. The purpose of this study is to determine whether one of the following two combinations: cetuximab plus chemotherapy, or cetuximab plus bevacizumab plus chemotherapy, is better than than the combination of bevacizumab with chemotherapy in patients who do not have K-ras mutations in their tumor tissues.
Eligibility Criteria
Patients with colon or rectal cancer
Primary Investigator(s)
- Bhoomi Mehrotra, MD